Buy Sunisam 12.5mg in UAE | Ernest Oncology – Oncology Meds Supplier

Sunisam 12.5mg Capsule: Advanced Multi-Kinase Inhibitor for Targeted Oncology

Are you searching for a reliable Sunisam 12.5 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of high-authority oncology medications. We provide high-quality pharmaceutical solutions to the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring seamless logistics and professional B2B service.

Product Overview: What is Sunisam 12.5 mg?

Sunisam 12.5 mg is an oral targeted therapy medication containing Sunitinib. It belongs to the class of Tyrosine Kinase Inhibitors (TKIs). Unlike traditional chemotherapy, which attacks all rapidly dividing cells, Sunisam is designed to interfere with specific molecules involved in the growth, progression, and spread of cancer.

Key Therapeutic Indications:

Sunisam 12.5 mg is primarily utilized in the management of:

• Advanced Renal Cell Carcinoma (RCC): A primary treatment for metastatic kidney cancer.

• Gastrointestinal Stromal Tumor (GIST): For patients who have not responded to or cannot tolerate imatinib therapy.

• Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors located in the pancreas.

• Adjuvant RCC Treatment: To reduce the risk of cancer returning after surgical removal of the kidney.

Mechanism of Action: How Sunisam Works:

Sunisam works by inhibiting multiple receptor tyrosine kinases (RTKs) that are often overexpressed in malignant tumors.

1. Anti-Angiogenesis: It targets VEGFR (Vascular Endothelial Growth Factor Receptors), which effectively cuts off the blood supply that tumors need to grow and survive.

2. Proliferation Inhibition: It blocks PDGFR and KIT receptors, signaling pathways that drive the division and survival of cancer cells.

3. Metastasis Reduction: By disrupting these vital cellular communications, Sunisam helps prevent the cancer from spreading to other organs.

Dosage and Administration:

• Cycle-Based Dosing: For RCC and GIST, a common regimen is 50 mg (multiple 12.5 mg capsules) daily for 4 weeks, followed by a 2-week rest period (the 4/2 schedule).

• Continuous Dosing: For pancreatic tumors, a continuous daily dose (often 37.5 mg) is standard.

• Method: Should be swallowed whole with water, with or without food.

• Crucial Precaution: Patients must avoid grapefruit and grapefruit juice, as they can increase the levels of Sunitinib in the blood to toxic levels.

Common Side Effects:

Monitoring is essential for patients on Sunisam to manage potential side effects:

• Fatigue and mucosal inflammation.

• Hand-Foot Syndrome: Redness, swelling, or pain on the palms and soles.

• Hypertension (High Blood Pressure).

• Altered taste or skin/hair discoloration.

Why Partner with Ernest Oncology for Sunisam 12.5 mg?

• Global Logistics Mastery: Direct shipping and customs handling for USA, UK, UAE, Australia, and South Africa.

• Authentic Indian Exports: We ensure all products are sourced from reputable, GMP-compliant manufacturers.

• Bulk Supply Availability: Constant inventory for hospitals, oncology centers, and international pharmacies.

• Competitive B2B Pricing: Optimized costs for international distributors and healthcare providers.